CorNeat Vision, an Israeli ophthalmic medical devices startup, announced it has completed the design and development stage of its revolutionary cornea implant (CorNeat KPro/Keratoprosthesis), an associated implantation tool and dedicated manufacturing process. Following solution validation in NZW rabbits, the company is currently initiating formal biocompatibility and safety tests toward first implantation in humans by mid-2018. The solution will be exposed for the first time to selected members of the ophthalmic community at the XXXV European Society of Cataract and Refractive Surgeons Congress (ESCRS) in Lisbon, Portugal October 7-11, 2017.
The CorNeat KPro implant is a patent-pending synthetic cornea that utilizes advanced cell technology to integrate artificial optics within resident ocular tissue. The CorNeat KPro is produced using nanoscale chemical engineering that stimulates cellular growth. Unlike previous devices, which attempted to integrate optics into the native cornea, the CorNeat KPro leverages a virtual space under the conjunctiva that is rich with fibroblast cells that heals quickly and provides robust long-term integration. Combined with a novel and simple 30-minute surgical procedure, the CorNeat KPro provides an esthetic, efficient, scalable remedy for millions of people with cornea-related visual impairments and is far superior to any available biological and synthetic alternatives.
A short animated movie that demonstrates the implantation and integration of the CorNeat KPro device to the human eye is available in the following link: www.corneat.com/product-animation.
"Corneal pathology is the second leading cause of blindness worldwide with 20-30 million patients in need of a remedy and around 2 million new cases/year, CorNeat Vision CEO and VP R&D, Mr. Almog Aley-Raz, said in a company news release. "Though a profound cause of distress and disability, existing solutions, such as corneal transplantation, are carried out only about 200,000 times/year worldwide. Together, corneal transplantation, and to a much lesser extent artificial implants (KPros), address only 5%-10% of cases, "There exists an urgent need for an efficient, long-lasting and affordable solution to corneal pathology, injury and blindness, which would alleviate the suffering and disability of millions of people. We are very excited to reach this important milestone in the development of our solution and are confident that the CorNeat KPro will enable millions to regain their sight."
"The groundbreaking results obtained in our proof of concept which is backed by conclusive histopathological evidence, are extremely encouraging. We are entering the next phase with great confidence that CorNeat KPro will address corneal blindness just like IOLs addressed cataract", Dr. Gilad Litvin, CorNeat Vision’s Chief Medical Officer and founder and the CorNeat KPro inventor, said in the news release. "Our novel IP, now cleared by the European Patent Office, ensures long-term retention, robust integration into the eye and an operation that is significantly shorter and simpler than Keratoplasty (corneal transplantation).